Arteriocyte Medical Systems Inc. – Trademark Portfolio
Entity Type: 03
Arteriocyte Medical Systems Inc. holds 16 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 15 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 4 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include TRUPRP and MAGELLAN. The owner is based in Hopkinton, MA.
45 South Street Suite C
Hopkinton, MA 01748
Showing of trademarks Trademarks
Trademark Classifications
Arteriocyte Medical Systems Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does Arteriocyte Medical Systems Inc. have?
Arteriocyte Medical Systems Inc. has 16 U.S. trademarks filed with the USPTO. Of these, 2 registered, 9 abandoned, 5 cancelled.
What trademark classes does Arteriocyte Medical Systems Inc. file in?
Arteriocyte Medical Systems Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 1 (Chemicals), Class 9 (Computers & Electronics), Class 7 (Machinery). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.
What are Arteriocyte Medical Systems Inc.'s most well-known trademarks?
Arteriocyte Medical Systems Inc.'s registered trademark portfolio includes well-known marks such as TRUPRP and MAGELLAN. These are among 2 currently registered trademarks in the portfolio.
What is Arteriocyte Medical Systems Inc.'s trademark registration success rate?
Arteriocyte Medical Systems Inc. has a 13% trademark registration rate, with 2 out of 16 resolved applications resulting in successful registration. Currently, 0 applications are pending review.